Humanin 10mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Humanin was discovered in surviving neurons from an Alzheimer's brain, screened for factors that conferred resistance to amyloid-beta toxicity, and its identification established that the mitochondrial genome encodes signalling peptides at all. It acts through a cell-surface receptor complex involving CNTFR, WSX-1 and gp130, and also interacts with Bax to inhibit apoptosis. Circulating levels decline with age, which is the observation driving most of the longevity interest. MOTS-c, already in this catalogue, is the other well-characterised member of the same class.
Frequently Bought Together
Humanin 10mg
10mg
$199 USD
Bundle & Save
$234 USD
Save $14 USD
$279 USD
Save $29 USD
$304 USD
Save $44 USD
$339 USD
Save $69 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Peptide Purification: Methods, Techniques, and Quality Considerations for Research
Explore peptide purification methods including HPLC, techniques, and quality considerations for research peptide integrity.
Humanin: Mitochondrial-Derived Peptide for Cytoprotection and Longevity Research
Explore Humanin, a mitochondrial-derived peptide investigated for cytoprotection, anti-apoptosis, and longevity mechanisms in preclinical research.
FDA Urged to Reject Untested Peptides in Compounded Medications
The Information Technology and Innovation Foundation (ITIF) published a blog on July 22, 2026, arguing that the FDA should not allow untested peptides to be added into patients' medications. The piece warns that adding unapproved peptides to compounded drugs poses serious safety risks without proven benefits, and calls for stronger regulatory oversight to protect public health.